Press release
Renal Cancer Clinical Pipeline | 75+ Companies, Including Genentech, AstraZeneca, Allogene Therapeutics, and Merck Driving the Next Breakthroughs
Renal Cancer Clinical Pipeline
DelveInsight's 'Renal Cancer Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Renal Cancer therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Renal Cancer pipeline domain.
For Renal Cancer emerging drugs, the Renal Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Renal Cancer Pipeline Report
• DelveInsight's Renal Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline drugs for Renal Cancer treatment.
• The leading Renal Cancer companies include Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co., Inc, X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals, Inc, Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others are evaluating their lead assets to improve the Renal Cancer treatment landscape.
• Key Renal Cancer pipeline therapies in various stages of development include Belzutifan/Everolimus, Orellanine, Atezolizumab/Cabozantinib, HB0025, ADI-270, IPI-549/Bevacizumab, APL-101 Oral Capsules, MDX2001, Olaparib, MK-4830, ALLO-316, and others.
• In Feb 2025, Telix Pharmaceuticals announced that the FDA accepted the Biologics License Application (BLA) for TLX250-CDx (Zircaix®), a breakthrough kidney cancer PET imaging agent. The FDA granted a Priority Review and set a PDUFA date of August 27, 2025, for a potential U.S. launch.
Request a sample and discover the recent breakthroughs happening in the Renal Cancer pipeline landscape @ https://www.delveinsight.com/report-store/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Renal Cancer Overview
Renal cell carcinoma (RCC), also known as hypernephroma, renal adenocarcinoma, or kidney cancer, is a malignancy that originates in the tubules of the kidney. In its early stages, RCC is often asymptomatic, but as it progresses, symptoms may include abdominal lumps, fatigue, unexplained weight loss, blood in the urine, appetite loss, vision problems, and excessive hair growth. RCC accounts for approximately 85% of adult kidney cancers and remains clinically silent for much of its course. Only about 10% of patients present with the classic triad of flank pain, hematuria, and flank mass, while roughly 33% of cases develop metastatic spread, complicating treatment due to the limited efficacy of current therapies.
As RCC advances, symptoms such as lower back pain, fever, night sweats, and high blood pressure may appear. Several risk factors contribute to RCC, including obesity, smoking, chronic kidney disease, genetic predisposition, high blood pressure, thyroid cancer, and diabetes. Diagnosis involves physical examinations, CT scans, blood tests, urine analysis, and biopsies. Treatment strategies include targeted therapies that inhibit tumor growth by blocking specific proteins or blood vessels, using drugs such as axitinib, bevacizumab, cabozantinib, everolimus, lenvatinib, nivolumab, pazopanib, sorafenib, sunitinib, and temsirolimus. Immunotherapy and chemotherapy also play roles in RCC management, with a focus on improving patient outcomes and controlling disease progression.
Find out more about Renal Cancer medication @ https://www.delveinsight.com/report-store/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Renal Cancer Treatment Analysis: Drug Profile
Atezolizumab : Genentech
Atezolizumab is a monoclonal antibody. It is designed to bind with a protein called PD-L1 expressed on tumor cells and tumor-infiltrating immune cells by blocking its interactions with both PD-1 and B7.1 the drug candidate are programmed cell death-1 ligand-1 inhibitors. Currently it is in Phase III stage of clinical trial evaluation to treat Renal Cancer.
Olaparib: AstraZeneca
Olaparib is a potent and orally active poly (ADP-ribose) polymerase PARP inhibitor thereby blocking the repair of single-strand DNA breaks resulting in synthetic lethality in BRCA-associated cancer cells, which have a dysfunction of another DNA repair pathway - homologous recombination being developed for the treatment of renal cell carcinoma. Currently being evaluated in the Phase II studies.
MK-4830 : Merck & Co., Inc
MK-4830 is an investigational first-in-class human monoclonal antibody that inhibits the binding of immunoglobulin-like transcript 4 (ILT-4) to its ligands. The drug candidate is being developed in combination with KEYTRUDA. MK-4830 is being developed under an agreement with Agenus Inc. Currently the drug is being evaluated in Phase II for the treatment of Renal Cancer.
Key Renal Cancer Therapies and Companies
• Belzutifan/Everolimus: Merck Sharp & Dohme LLC
• Orellanine: Oncorena AB
• Atezolizumab/Cabozantinib: Hoffmann-La Roche
• HB0025: Huabo Biopharm Co., Ltd.
• ADI-270: Adicet Therapeutics
• IPI-549/Bevacizumab: Infinity Pharmaceuticals, Inc.
• APL-101 Oral Capsules: Apollomics Inc.
• MDX2001: ModeX Therapeutics
• Olaparib: AstraZeneca
• MK-4830 : Merck & Co., Inc
• ALLO-316 : Allogene Therapeutics
Learn more about the novel and emerging Renal Cancer pipeline therapies @ https://www.delveinsight.com/report-store/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Renal Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Renal Cancer Pipeline Report
• Coverage: Global
• Key Renal Cancer Companies: Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co., Inc, X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals, Inc, Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
• Key Renal Cancer Pipeline Therapies: Belzutifan/Everolimus, Orellanine, Atezolizumab/Cabozantinib, HB0025, ADI-270, IPI-549/Bevacizumab, APL-101 Oral Capsules, MDX2001, Olaparib, MK-4830, ALLO-316, and others.
Dive deep into rich insights for drugs used for Renal Cancer treatment; visit @ https://www.delveinsight.com/report-store/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Renal Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Renal Cancer Pipeline Therapeutics
6. Renal Cancer Pipeline: Late-Stage Products (Phase III)
7. Renal Cancer Pipeline: Late-Stage Products (Phase III)
8. Renal Cancer Pipeline: Mid-Stage Products (Phase II)
9. Renal Cancer Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Renal Cancer Clinical Pipeline | 75+ Companies, Including Genentech, AstraZeneca, Allogene Therapeutics, and Merck Driving the Next Breakthroughs here
News-ID: 3922243 • Views: …
More Releases from DelveInsight
Hypovolemia Pipeline Insight 2025: Next-Gen Volume Expanders, Oxygen Therapeutic …
DelveInsight's "Hypovolemia - Pipeline Insight, 2025" provides a comprehensive overview of the therapeutic innovations aimed at managing this life-threatening condition characterized by rapid loss of circulating blood volume. Often triggered by trauma, surgery, gastrointestinal bleeding, or obstetric emergencies, hypovolemia remains a critical care challenge due to limited availability of blood products, logistical hurdles in emergency settings, and complications associated with excessive crystalloid use.
The 2025 pipeline emphasizes the development of next-generation…
Abdominal Aortic Aneurysm (AAA) Repair Devices Market to Register a CAGR of 5.70 …
The global abdominal aortic aneurysm (AAA) repair devices market is poised for steady growth through 2032, supported by the rising prevalence of aneurysms among the aging population, lifestyle-related risk factors such as smoking and hypertension, and improved diagnostic detection rates. The increasing adoption of minimally invasive endovascular aneurysm repair (EVAR) devices over traditional open surgery is enhancing procedural safety, reducing hospital stays, and improving patient outcomes.
Moreover, advancements in stent graft…
Adult-Onset Still Disease Pipeline Insight 2025: IL-1/IL-6 Blockade, JAK Inhibit …
DelveInsight's "Adult-Onset Still Disease - Pipeline Insight, 2025" provides a detailed overview of the evolving therapeutic landscape for this rare systemic autoinflammatory disorder. Traditionally reliant on corticosteroids and conventional DMARDs, Adult-Onset Still Disease (AOSD) has long posed clinical challenges due to its relapsing course, systemic inflammation, and risk of complications such as macrophage activation syndrome.
The 2025 pipeline highlights the growing dominance of targeted biologics, particularly IL-1 and IL-6 inhibitors, which…
Laparoscopy Devices Market to Witness Robust Growth by 2032, Driven by Rising Mi …
The laparoscopy devices market is expected to grow steadily through 2032, driven by the increasing adoption of minimally invasive surgical procedures across gastrointestinal, gynecological, and urological specialties. Advances in high-definition imaging, robotic-assisted systems, and energy-based surgical tools are enhancing precision, reducing recovery times, and improving patient outcomes. Additionally, the rising prevalence of chronic diseases, growing geriatric population, and increasing awareness of minimally invasive surgery benefits are expected to further propel…
More Releases for Renal
Advancements in Renal Dialysis Equipment Trend: A Crucial Influence on the Renal …
What market dynamics are playing a key role in accelerating the growth of the renal dialysis equipment market?
The escalating incidence of chronic kidney disease is projected to boost the expansion of the renal dialysis equipment market. Chronic kidney disease, a term that describes the slow and progressive decline of kidney function, can ultimately result in kidney failure and other severe health conditions. This disease is linked with several risk factors…
Renal Osteodystrophy Market: An In-Depth Analysis
The Renal Osteodystrophy Market was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 7.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032.
Renal Osteodystrophy Market Overview
The Renal Osteodystrophy Market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease (CKD) and the associated bone disorders. Advancements in diagnostic techniques have enhanced early…
Shaping the Renal Dialysis Equipment Market in 2025: Advancements in Renal Dialy …
How Big Is the Renal Dialysis Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent years, the renal dialysis equipment market has seen robust growth. It's projected to increase from $19.52 billion in 2024 to $20.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to growth in the historic period include comprehensive training and support programs, substantial research and development…
Transforming the Veterinary Renal Disease Market in 2025: Increasing Pet Ownersh …
"What Is the Expected Size and Growth Rate of the Veterinary Renal Disease Market?
The market size for veterinary kidney diseases has seen profound growth recently. It is set to expand from $15.5 billion in 2024 to $16.63 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors contributed to this growth during the historical period, including heightened initiatives to increase disease awareness, a shift in…
Renal Cancer Pipeline Outlook Report 2024
DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period…
